American College of Medical Toxicology and the American Academy of Clinical Toxicology Position Statement: Nalmefene Should Not Replace Naloxone as the Primary Opioid Antidote at This Time-Reference-Cited by-同舟云学术

American College of Medical Toxicology and the American Academy of Clinical Toxicology Position Statement: Nalmefene Should Not Replace Naloxone as the Primary Opioid Antidote at This Time

Published:2023-11-30 Issue:1 Volume:20 Page:64-67
ISSN:1556-9039
Container-title:Journal of Medical Toxicology
language:en
Short-container-title:J. Med. Toxicol.

Author:

Stolbach Andrew I.,Mazer-Amirshahi Maryann,Nelson Lewis S.,Cole Jon B.

Publisher

Springer Science and Business Media LLC

Subject

Health, Toxicology and Mutagenesis,Toxicology

Link

https://link.springer.com/content/pdf/10.1007/s13181-023-00981-z.pdf

Reference28 articles.

1. Drug overdose deaths remained high in 2021 [Internet]. Centers for Disease Control and Prevention. 2023. Available from: https://www.cdc.gov/drugoverdose/deaths/index.html. Accessed 26 Nov 2023.

2. Harris E. FDA approves nalmefene, a longer-lasting opioid reversal nasal spray. JAMA. 2023;329:2012.

3. Ohmeda Pharmaceutical Products Division, Inc. Investigational New Drug approval letter for nalmefene hydrochloride injection (Revex®) [Internet]. U.S. Food and Drug Administration. 1995. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/nda/pre96/020459Orig1s000rev.pdf. Accessed 26 Nov 2023.

4. Skolnick P. Treatment of overdose in the synthetic opioid era. Pharmacol Ther. 2022;233:108019.

5. Britch SC, Walsh SL. Treatment of opioid overdose: current approaches and recent advances. Psychopharmacology. 2022;239:2063–81.

Cited by 1 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Challenges with current diagnosis and treatment strategies for precipitated opioid withdrawal in the emergency department and the role of the pharmacist;American Journal of Health-System Pharmacy;2024-07-19